The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19
Background Limited research has studied the influence of social determinants of health (SDoH) on the receipt, disease risk, and subsequent effectiveness of neutralizing monoclonal antibodies (nMAbs) for outpatient treatment of COVID-19. Objective To examine the influence of SDoH variables on receiving nMAb treatments and the risk of a poor COVID-19 outcome, as well as nMAb treatment effectiveness across SDoH subgroups. Design Retrospective observational study utilizing electronic health record data from four health systems. SDoH variables analyzed included race, ethnicity, insurance, marital status, Area Deprivation Index, and population density. Participants COVID-19 patients who met at least one emergency use authorization criterion for nMAb treatment. Main Measure We used binary logistic regression to examine the influence of SDoH variables on receiving nMAb treatments and risk of a poor outcome from COVID-19 and marginal structural models to study treatment effectiveness. Results The study population included 25,241 (15.1%) nMAb-treated and 141,942 (84.9%) non-treated patients. Black or African American patients were less likely to receive treatment than white non-Hispanic patients (adjusted odds ratio (OR) = 0.86; 95% CI = 0.82–0.91). Patients who were on Medicaid, divorced or widowed, living in rural areas, or living in areas with the highest Area Deprivation Index (most vulnerable) had lower odds of receiving nMAb treatment, but a higher risk of a poor outcome. For example, compared to patients on private insurance, Medicaid patients had 0.89 (95% CI = 0.84–0.93) times the odds of receiving nMAb treatment, but 1.18 (95% CI = 1.13–1.24) times the odds of a poor COVID-19 outcome. Age, comorbidities, and COVID-19 vaccination status had a stronger influence on risk of a poor outcome than SDoH variables. nMAb treatment benefited all SDoH subgroups with lower rates of 14-day hospitalization and 30-day mortality. Conclusion Disparities existed in receiving nMAbs within SDoH subgroups despite the benefit of treatment across subgroups..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of general internal medicine - 38(2023), 16 vom: 15. Sept., Seite 3472-3481 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ambrose, Nalini [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Society of General Internal Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11606-023-08324-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054045010 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054045010 | ||
| 003 | DE-627 | ||
| 005 | 20231212064652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231212s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11606-023-08324-y |2 doi | |
| 035 | |a (DE-627)SPR054045010 | ||
| 035 | |a (SPR)s11606-023-08324-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ambrose, Nalini |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Society of General Internal Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background Limited research has studied the influence of social determinants of health (SDoH) on the receipt, disease risk, and subsequent effectiveness of neutralizing monoclonal antibodies (nMAbs) for outpatient treatment of COVID-19. Objective To examine the influence of SDoH variables on receiving nMAb treatments and the risk of a poor COVID-19 outcome, as well as nMAb treatment effectiveness across SDoH subgroups. Design Retrospective observational study utilizing electronic health record data from four health systems. SDoH variables analyzed included race, ethnicity, insurance, marital status, Area Deprivation Index, and population density. Participants COVID-19 patients who met at least one emergency use authorization criterion for nMAb treatment. Main Measure We used binary logistic regression to examine the influence of SDoH variables on receiving nMAb treatments and risk of a poor outcome from COVID-19 and marginal structural models to study treatment effectiveness. Results The study population included 25,241 (15.1%) nMAb-treated and 141,942 (84.9%) non-treated patients. Black or African American patients were less likely to receive treatment than white non-Hispanic patients (adjusted odds ratio (OR) = 0.86; 95% CI = 0.82–0.91). Patients who were on Medicaid, divorced or widowed, living in rural areas, or living in areas with the highest Area Deprivation Index (most vulnerable) had lower odds of receiving nMAb treatment, but a higher risk of a poor outcome. For example, compared to patients on private insurance, Medicaid patients had 0.89 (95% CI = 0.84–0.93) times the odds of receiving nMAb treatment, but 1.18 (95% CI = 1.13–1.24) times the odds of a poor COVID-19 outcome. Age, comorbidities, and COVID-19 vaccination status had a stronger influence on risk of a poor outcome than SDoH variables. nMAb treatment benefited all SDoH subgroups with lower rates of 14-day hospitalization and 30-day mortality. Conclusion Disparities existed in receiving nMAbs within SDoH subgroups despite the benefit of treatment across subgroups. | ||
| 700 | 1 | |a Amin, Alpesh |4 aut | |
| 700 | 1 | |a Anderson, Brian |4 aut | |
| 700 | 1 | |a Bertagnolli, Monica |4 aut | |
| 700 | 1 | |a Campion, Francis |0 (orcid)0000-0002-0757-9305 |4 aut | |
| 700 | 1 | |a Chow, Dan |4 aut | |
| 700 | 1 | |a Danan, Risa |4 aut | |
| 700 | 1 | |a D’Arinzo, Lauren |4 aut | |
| 700 | 1 | |a Drews, Ashley |4 aut | |
| 700 | 1 | |a Erlandson, Karl |4 aut | |
| 700 | 1 | |a Fitzgerald, Kristin |4 aut | |
| 700 | 1 | |a Gaspar, Fraser |4 aut | |
| 700 | 1 | |a Gong, Carlene |4 aut | |
| 700 | 1 | |a Hanna, George |4 aut | |
| 700 | 1 | |a Hawley, Heather |4 aut | |
| 700 | 1 | |a Jones, Stephen |4 aut | |
| 700 | 1 | |a Lopansri, Bert |4 aut | |
| 700 | 1 | |a Mullen, Ty |4 aut | |
| 700 | 1 | |a Musser, James |4 aut | |
| 700 | 1 | |a O’Horo, John |4 aut | |
| 700 | 1 | |a Piantadosi, Steven |4 aut | |
| 700 | 1 | |a Pritt, Bobbi |4 aut | |
| 700 | 1 | |a Razonable, Raymund |4 aut | |
| 700 | 1 | |a Rele, Shyam |4 aut | |
| 700 | 1 | |a Roberts, Seth |4 aut | |
| 700 | 1 | |a Sandmeyer, Suzanne |4 aut | |
| 700 | 1 | |a Stein, David |4 aut | |
| 700 | 1 | |a Te, Jerez |4 aut | |
| 700 | 1 | |a Vahidy, Farhaan |4 aut | |
| 700 | 1 | |a Webb, Brandon |4 aut | |
| 700 | 1 | |a Welch, Nathan |4 aut | |
| 700 | 1 | |a Wood, Alexander |4 aut | |
| 700 | 1 | |a Yttri, Jennifer |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of general internal medicine |d New York, NY : Springer, 1986 |g 38(2023), 16 vom: 15. Sept., Seite 3472-3481 |w (DE-627)SPR021085749 |w (DE-600)2006784-7 |x 1525-1497 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:16 |g day:15 |g month:09 |g pages:3472-3481 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11606-023-08324-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 16 |b 15 |c 09 |h 3472-3481 | ||